Monitor upcoming clinical readouts in 2026, especially the Phase 3 ovarian cancer topline data in 2H26, which could be a major value catalyst. The improved cash runway reduces near-term dilution risk.
Price Chart
Executive Summary
Genelux reported its 2025 financial results, showing a narrowed net loss and increased R&D spend due to its Phase 3 ovarian cancer trial. The company highlighted interim lung cancer data showing partial responses in SCLC and early activity in NSCLC, appointed a new CMO, and raised $18.5M in net proceeds, giving it a pro forma cash balance of $33.1M to fund operations into 1Q27.
Key Financial Metrics
Key Facts
- Net loss narrowed to $32.1M ($0.86/share) in 2025 from $29.9M ($0.95/share) in 2024
- R&D expenses increased to $19.9M in 2025 from $19.0M in 2024 due to Phase 3 trial costs
- Raised $18.5M in net proceeds from a January 2026 public offering, bringing pro forma cash to $33.1M as of Dec 31, 2025
- Cash expected to fund operations into 1Q27
- Interim data: 33% partial response rate (3/9) in SCLC, 60% disease control rate in NSCLC (3/5)
- Topline Phase 3 ovarian cancer data expected in 2H26
Financial Impact
Net loss increased slightly in absolute terms but improved on a per-share basis due to share count increase; cash position strengthened significantly with $18.5M raised
Risk Factors
- Clinical trial results may not meet expectations, especially in the pivotal Phase 3 ovarian cancer study
- Small patient cohorts in early lung cancer trials limit statistical significance
- High cash burn rate: ~$32M net loss in 2025 on just $8K in revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259445 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 2, 2026 7w ago | Insider Cluster | $2.52 $2.53 | ▼ −0.40% | ▼ −1.52% | $2.00 (+20.63%) |
Aug 13, 2026 10w ago | Press Release | $2.74 $2.54 | ▼ −7.30% | ▼ −5.31% | $2.00 (−27.01%) |
Jun 4, 2026 20w ago | Insider Cluster | $2.93 $3.02 | ▲ +3.07% | ▲ +1.21% | $2.00 (−31.74%) |
May 11, 2026 24w ago | Insider Cluster | $2.90 $2.98 | ▲ +2.76% | ▲ +3.06% | $2.00 (−31.03%) |
Apr 29, 2026 25w ago | DEFA14A | $2.50 $3.06 | ▲ +22.40% | ▲ +16.94% | $2.00 (−20.00%) |
Mar 24, 2026 31w ago | Insider Cluster | $2.42 $2.54 | ▲ +4.96% | ▼ −3.94% | $2.00 (−17.36%) |
Mar 19, 2026 31w ago | Press Release | $2.40 $2.65 | ▲ +10.42% | ▲ +1.10% | $2.00 (−16.67%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers